-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Lineage Cell Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2012 to Q3 2024.
- Lineage Cell Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $1.33M, a 4.81% increase year-over-year.
- Lineage Cell Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $4.82M.
- Lineage Cell Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $4.64M, a 8.23% increase from 2022.
- Lineage Cell Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4.29M.
- Lineage Cell Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2018 was $298M.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)